TLX Stock Forecast & Price Target

Telix Pharmaceuticals is attractive fundamentally because its core Illuccix franchise continues to generate scale, with 3Q26 revenue of $245MM and Precision Medicine revenue of $201MM, while management still expects FY26 revenue above $1B and Precision Medicine growth of more than 25%. Its outlook is further strengthened by multiple near-term catalysts, including Pixclara’s first U.S. commercial neuro-oncology presence, BiPASS completion with a potential label expansion that could roughly double the addressable market, and ongoing progress across TLX591-Tx, TLX597-Tx, Zircaix, and Illuccix’s Japan filing. The proposed ITM acquisition adds vertically integrated isotope supply, broader global distribution, and a profitable isotope business that generated $273MM of revenue in 2025, improving supply security and expanding Telix’s growth profile beyond prostate imaging.

Telix Pharmaceuticals is exposed to meaningful downside because its valuation depends heavily on a narrow set of catalysts, while the company explicitly faces clinical and regulatory failures across its clinical-stage programs. A failure to advance pipeline assets in urologic oncology, neuro-oncology, musculoskeletal oncology, or hematology would weaken the long-term growth story, especially since most revenue currently comes from Illuccix, making execution risk concentrated rather than diversified. The negative outlook is reinforced by the stated risk that the company may be unable to achieve sales estimates, which would pressure fundamentals and undermine confidence in both its current commercial performance and future development prospects.